Daetwyler Holding (DAE) AI Stock Analysis

• Market Cap: CHF2.56B
• Dividend Yield: 1.96%
• Average Volume (3M): 12.37K
• Price to Earnings (P/E): 34.4
• Beta (1Y): 0.56
• Revenue Growth: -2.06%
• EPS Growth: -58.53%
• Country: CH
• Employees: 8,030
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial - Distribution
• EPS (TTM): 2.52
• Shares Outstanding: 12,600,000
• 10 Day Avg. Volume: 11,336
• 30 Day Avg. Volume: 12,370
• PEG Ratio: 0.22
• Price to Book (P/B): 7.53
• Price to Sales (P/S): 2.53
• P/FCF Ratio: 21.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF193.00
• Price Target Upside: 27.98% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 5.97
• Revenue Forecast (FY): CHF1.20B

• Rating: 61 Neutral
• Price Target: CHF158.00 ▲(4.77% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is driven mainly by mid-tier financial performance (solid cash generation but elevated leverage and uneven profitability) and supportive technical momentum (price above key moving averages with positive MACD). These positives are tempered by a relatively expensive valuation (high P/E and modest yield).

Positive Factors

Consistent cash generation

Sustained positive operating and free cash flow across multiple years provides durable internal funding for capex, working capital and debt repayment. This steady cash conversion supports reinvestment in tooling and validation processes critical to long-term contracts in regulated markets, improving resilience.

2025 revenue rebound

A clear revenue recovery in 2025 after a flat-to-down period suggests demand normalization and successful commercial execution on lost/paused programs. If sustained, this improves utilization of specialized manufacturing assets and helps restore operating leverage, supporting more durable margin and cash-flow recovery.

B2B model in regulated healthcare with value-added services

Deep exposure to regulated pharma and embedded engineering/validation services creates high switching costs and recurring demand. Validated materials and long qualification cycles favor entrenched suppliers, enabling multi-year contracts and stickier revenue streams that underpin durable business stability and predictable servicing needs.

Negative Factors

Elevated leverage vs. history

Materially higher debt versus prior years limits financial flexibility and raises interest-service risk if margins or cash flows slip. Elevated leverage constrains ability to fund strategic investments or absorb cyclical demand shocks, making long-term growth and capital allocation more dependent on consistent cash generation.

Volatile profitability and margins

Significant margin compression and profit volatility reduce forecasting reliability and weaken capacity to build reserves or invest in product validation. For a supplier to regulated industries, inconsistent profitability undermines negotiating power on pricing and may force trade-offs between margin protection and contract retention.

Stretched top-line consistency

Prolonged flat or declining revenue through 2022–2024 indicates structural exposure to lost programs or cyclical end-markets. Even with a rebound, the prior erosion suggests business growth is uneven, making long-term planning and deleveraging slower and increasing dependence on winning and scaling new programs to restore historical growth.

Daetwyler Holding Business Overview & Revenue Model

Company Description

Dätwyler Holding AG manufactures and sells elastomer components for health care, mobility, oil and gas, and food and beverage industries in Europe, North America, South America, and Asia. It operates through Healthcare Solutions and Industrial Solutions segments. The Healthcare Solutions segment offers rubber components for prefilled syringes, pens, and injection systems; components and closures for injectable drugs in vials; and rubber components for blood collection systems, IV administration sets, disposable syringes, diagnostics and medical devices, etc. The Industrial Solutions segment products include electromobility solutions, active assistance and safety systems, brake systems, fuel and engine management, exhaust gas aftertreatment, and sealing components for upstream systems, power tools, water, and process industries. The company was founded in 1915 and is based in Altdorf, Switzerland. Dätwyler Holding AG is a subsidiary of Pema Holding AG.

How the Company Makes Money

Daetwyler makes money mainly by selling engineered sealing and elastomer components and systems to business customers (B2B). Its largest revenue stream is the supply of components for the healthcare and pharmaceutical industry—such as elastomer parts used in drug packaging and delivery—where customers typically require validated materials, consistent quality, and long-term supply reliability; this supports recurring demand tied to customers’ ongoing drug production. A second core revenue stream comes from industrial and mobility applications, where Daetwyler sells sealing solutions and precision elastomer components used in technical systems (including automotive-related uses), with revenue driven by production volumes, program wins, and ongoing replacement/production orders. In addition to component sales, the company generates revenue from value-added services embedded in customer programs (e.g., engineering support, material and process expertise, qualification/validation support required in regulated markets, and customized manufacturing), which help secure long-term customer relationships and can improve margins. Specific information on material licensing, explicit royalty streams, or named significant partnerships is null.

Daetwyler Holding Financial Statement Overview

Summary

Cash flow is a relative strength with consistently positive operating and free cash flow (despite some variability). Offsetting this, profitability has been volatile since the 2021–2022 peak and the balance sheet remains relatively leveraged (debt well above equity in 2022–2024, only partially improved in 2025), keeping overall financial quality mid-range.

Income Statement

Revenue has been relatively flat to down from 2022–2024, followed by a rebound in 2025 (about +21% year over year). However, profitability has been volatile: margins stepped down materially after 2021, net income fell sharply in 2024, and while 2025 shows recovery, earnings power still appears below the 2021–2022 peak. The mix of improving growth but uneven margins keeps the income statement in the middle of the pack.

Balance Sheet

Leverage is the key constraint. Debt moved from very low levels in 2021 to meaningfully higher in 2022–2024, with debt running well above equity (debt-to-equity around 1.6–1.7 in 2022–2024). While total debt came down in 2025, the capital structure remains more leveraged than earlier years, limiting flexibility. Equity has been fairly stable, but overall balance-sheet risk is elevated versus the company’s own history.

Cash Flow

Cash generation is a relative strength: operating cash flow has been consistently solid across the period, and free cash flow is positive each year (with a sharp dip in 2022 followed by a strong rebound in 2023–2025). The main weakness is variability—free cash flow growth has been choppy and slightly negative in the last two years—suggesting execution and/or working-capital swings. Still, the company is producing meaningful free cash flow to support debt reduction and reinvestment.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.10B	1.11B	1.15B	1.15B	947.60M
Gross Profit	257.90M	238.30M	240.20M	255.20M	247.60M
EBITDA	188.70M	144.10M	187.20M	224.30M	225.50M
Net Income	80.80M	31.10M	66.80M	104.80M	194.00M
Balance Sheet
Total Assets	1.07B	1.15B	1.20B	1.30B	1.26B
Cash, Cash Equivalents and Short-Term Investments	125.50M	127.40M	122.50M	101.30M	279.60M
Total Debt	504.60M	574.40M	639.60M	697.40M	150.50M
Total Liabilities	695.90M	781.70M	814.60M	895.40M	312.70M
Stockholders Equity	369.40M	368.50M	386.20M	403.60M	948.30M
Cash Flow
Free Cash Flow	126.90M	127.50M	135.40M	18.40M	72.20M
Operating Cash Flow	173.80M	171.70M	194.90M	118.60M	183.50M
Investing Cash Flow	-44.40M	-43.80M	-58.20M	-701.50M	-23.10M
Financing Cash Flow	-126.10M	-124.90M	-109.70M	466.80M	-113.00M

Daetwyler Holding Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 150.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:DAE, the sentiment is Negative. The current price of 150.8 is below the 20-day moving average (MA) of 159.28, below the 50-day MA of 163.48, and above the 200-day MA of 145.74, indicating a neutral trend. The MACD of -4.23 indicates Positive momentum. The RSI at 33.73 is Neutral, neither overbought nor oversold. The STOCH value of 15.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:DAE.

Daetwyler Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KARN	73 Outperform	CHF1.95B	54.72	―	2.17%	11.43%	6.46%
AERO	67 Neutral	CHF1.80B	-26.55	―	―	-4.40%	―
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
DAE	61 Neutral	CHF2.56B	34.42	8.55%	1.96%	-2.06%	-58.53%
INRN	59 Neutral	CHF1.28B	33.61	―	1.46%	-3.67%	-12.95%
BOSN	58 Neutral	CHF1.09B	16.79	19.79%	2.51%	2.35%	1.92%
DOKA	52 Neutral	CHF2.11B	16.53	―	―	1.16%	132.26%